GT201400115A - Combinación farmacéutica antineurítica y composición - Google Patents

Combinación farmacéutica antineurítica y composición

Info

Publication number
GT201400115A
GT201400115A GT201400115A GT201400115A GT201400115A GT 201400115 A GT201400115 A GT 201400115A GT 201400115 A GT201400115 A GT 201400115A GT 201400115 A GT201400115 A GT 201400115A GT 201400115 A GT201400115 A GT 201400115A
Authority
GT
Guatemala
Prior art keywords
antineurítica
composición
pharmaceutical combination
combinations
pharmaceutical
Prior art date
Application number
GT201400115A
Other languages
English (en)
Inventor
Senosiain Arroyo Héctor
Angélica Arzola Paniagua María
Original Assignee
Laboratorios Senosiain S A De C V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48611941&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GT201400115(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Laboratorios Senosiain S A De C V filed Critical Laboratorios Senosiain S A De C V
Publication of GT201400115A publication Critical patent/GT201400115A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A61K31/51—Thiamines, e.g. vitamin B1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A COMBINACIONES FARMACÉUTICAS DE DOS ANTIEPILÉPTICOS, ASÍ COMO COMBINACIONES DE UN ANTIEPILÉPTICO, Y VITAMINAS DEL COMPLEJO B, EN DONDE LOS ANTIEPILÉPTICOS SE SELECCIONAN DE PREGABALINA Y OXCARBAZEPINA, Y LAS VITAMINAS SE SELECCIONAN DE VITAMINA B1 Y VITAMINA B12. TAMBIÉN SE REFIERE A COMPOSICIONES FARMACÉUTICAS QUE CONTIENEN DICHAS COMBINACIONES Y AL USO DE DICHAS COMPOSICIONES PARA EL TRATAMIENTO DEL DOLOR NEUROPÁTICO (DN).
GT201400115A 2011-12-16 2014-06-16 Combinación farmacéutica antineurítica y composición GT201400115A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MX2011014042A MX336979B (es) 2011-12-16 2011-12-16 Combinacion farmaceutica antineuritica y composiciones.

Publications (1)

Publication Number Publication Date
GT201400115A true GT201400115A (es) 2017-07-27

Family

ID=48611941

Family Applications (1)

Application Number Title Priority Date Filing Date
GT201400115A GT201400115A (es) 2011-12-16 2014-06-16 Combinación farmacéutica antineurítica y composición

Country Status (14)

Country Link
US (1) US20140323428A1 (es)
BR (1) BR112014014774A2 (es)
CA (1) CA2859487C (es)
CL (1) CL2014001581A1 (es)
CO (1) CO6990712A2 (es)
CR (1) CR20140283A (es)
DO (1) DOP2014000134A (es)
ES (1) ES2525952B1 (es)
GT (1) GT201400115A (es)
MX (1) MX336979B (es)
NI (1) NI201400058A (es)
PE (1) PE20141688A1 (es)
PL (1) PL231163B1 (es)
WO (1) WO2013088410A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2826470B1 (en) * 2013-07-19 2017-09-06 Arven Ilac Sanayi ve Ticaret A.S. Pharmaceutical combinations of pregabalin
MX2014008336A (es) 2014-07-07 2016-01-07 Pptm Internat S A R L Combinacion farmacologica antihiperalgesica, antialodinica y antiinflamatoria, composiciones farmaceuticas que la contienen, y su uso para el tratamiento del dolor neuropatico.

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2006127475A (ru) * 2003-12-29 2008-02-10 Джейсон МАКДЭВИТТ (US) Композиции и способы лечения рецидивирующих медицинских состояний
JP5452494B2 (ja) * 2007-10-09 2014-03-26 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング ベンフォチアミンと１または２種以上の医薬活性剤とを含む神経因性の疼痛状態の処置のための医薬組成物
US8394759B2 (en) * 2008-11-21 2013-03-12 Cymbiotics, Inc. Transdermal delivery of medicaments with combinations of cetylated fatty ester penetrant complexes

Also Published As

Publication number Publication date
US20140323428A1 (en) 2014-10-30
MX336979B (es) 2016-02-09
BR112014014774A2 (pt) 2017-06-13
DOP2014000134A (es) 2014-07-31
CL2014001581A1 (es) 2014-09-26
WO2013088410A1 (es) 2013-06-20
PL231163B1 (pl) 2019-01-31
NI201400058A (es) 2014-12-22
CO6990712A2 (es) 2014-07-10
ES2525952B1 (es) 2015-10-05
CR20140283A (es) 2015-03-11
CA2859487C (en) 2016-11-15
CA2859487A1 (en) 2013-06-20
ES2525952A1 (es) 2015-01-02
PE20141688A1 (es) 2014-12-03
PL409542A1 (pl) 2015-07-20
MX2011014042A (es) 2013-06-17

Similar Documents

Publication Publication Date Title
CY1122786T1 (el) Δοσολογικα σχηματα για ενωσεις κατηγοριας εχινοκανδινης
CR20150326A (es) Inhibidores de autotaxina
GT201700189A (es) Derivados de nucleósidos sustituidos útiles como agentes antineoplásicos
NI201600144A (es) Derivados de quinoxalina utiles como moduladores del fgfr cinasa
SV2018005687A (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cancer
CL2013001338A1 (es) Compuestos derivados de benzotieno-piridinas sustituidas, inhibidores de la replicacion del vih; composicion farmaceutica que los comprende; combinacion farmaceutica; kit farmaceutico; y su uso para el tratamiento del vih.
CL2014001829A1 (es) Compuestos derivados de indolizina; procedimiento de preparación; composiciones farmacéuticas que los contienen y uso en el tratamiento del cancer.
CL2015001437A1 (es) Derivados de pirimidin-2,4-diamina para el tratamiento de cancer
CL2014001793A1 (es) Compuestos derivados de 1,3,5-triazinas sustituidas y sus sales, como inhibidores de la idh2 mutante; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer.
CL2014001865A1 (es) Compuestos derivados de fosfatos; procedimiento de preparacion; composiciones farmaceuticas que los contienen y uso en el tratamiento del cancer.
CL2016000063A1 (es) Nuevos derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen.
DOP2018000062A (es) Piridinona dicaboxamidas para uso como inhibidores de bromodominio
DOP2016000253A (es) Nuevos compuestos
BR112016028845A2 (pt) composto, composição farmacêutica e uso de um composto
CO2019012767A2 (es) Compuesto de fenil-2-hidroxi-acetilamino-2-metil-fenilo
CL2017002170A1 (es) Desacetoxitubulisina h y análogos de esta.
CO2017002472A2 (es) Formulación de acetato de abiraterona
SV2017005412A (es) Compuestos de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo y usos de los mismos
ECSP14014778A (es) Composiciones derivadas de la quitosana
DOP2015000005A (es) Derivados de estra 1,3,5(10), 16 tetraeno 3 sustituidos, métodos para su preparación, preparaciones farmacéuticas que los contienen, así como su uso para la preparación de medicamentos
DOP2016000212A (es) Heterociclos condensados sustituidos como moduladores de gpr119 para el tratamiento de la diabetes, obesidad, dislipidemia y trastornos relacionados
SV2017005466A (es) Pirazolpiridinaminas como inhibidores de mknk1 y mknk2
BR112017022158A2 (pt) compostos, composições farmacêuticas e uso de um composto
CL2017000587A1 (es) Derivados de tetrahidroquinolina como inhibidores de bromodominio
PE20150167A1 (es) (r)-nifuratel, su uso para el tratamiento de las infecciones y sintesis de (r) y (s)-nifuratel